showed that anti-CD8α impaired CD8+ T cell-mediated antitumor immunity in orthotopic NAFLD-HCC and compromised immunotherapeutic efficacy. This evidence concerns the gene CD8A and metabolic dysfunction-associated steatotic liver disease.